Melanocortin Peptide Signaling in the Brain Controls Binge Drinking — and a Peptide Drug Can Reduce It | Research

The takeaway

Binge drinking alters melanocortin peptide levels in the hypothalamus, and the melanocortin receptor agonist melanotan-II reduced binge-like alcohol consumption in mice when delivered to the lateral hypothalamus, while the antagonist AgRP increased it.

Melanotan-II in the lateral hypothalamus reduced binge drinking
Direct delivery of the melanocortin peptide agonist to a specific brain region significantly reduced binge-like ethanol consumption, while the antagonist AgRP had the opposite effect — proving the melanocortin system bidirectionally controls alcohol intake

What the researchers found

Repeated binge-like ethanol drinking produced specific changes in melanocortin peptide expression in hypothalamic subregions: α-MSH (the appetite-suppressing peptide) was selectively decreased, while AgRP (the appetite-stimulating peptide) was selectively increased. These changes were specific to ethanol — not seen with sucrose or water controls.

Functional manipulation confirmed the significance: injection of the nonselective melanocortin receptor agonist melanotan-II (MTII) directly into the lateral hypothalamus (LH) significantly reduced binge-like ethanol consumption, while injection of the antagonist AgRP into the same region augmented drinking. These effects were region-specific to the LH, as they were not observed when drugs were delivered to other brain regions.

Why it matters

Binge drinking affects approximately 26% of US adults and is linked to liver disease, cardiovascular problems, and accidental death. Current treatments for alcohol use disorder (naltrexone, acamprosate, disulfiram) have limited effectiveness, and binge drinking specifically has no approved targeted therapy. The melanocortin system — which regulates both feeding and reward — represents a novel therapeutic target. The fact that a peptide drug (melanotan-II) reduced binge drinking in a specific brain region opens the door to developing targeted peptide or small-molecule melanocortin therapies for alcohol abuse.

How the study worked

Male C57BL/6J mice underwent 1, 3, or 6 cycles of the 'drinking in the dark' (DID) binge drinking protocol with ethanol, sucrose, or water. Brain tissue was processed by immunohistochemistry for α-MSH and AgRP expression in hypothalamic subregions. Site-directed microinjection was used to deliver melanotan-II (MCR agonist) or AgRP (MCR antagonist) into the lateral hypothalamus, and subsequent ethanol consumption was measured.

What this study cannot tell us

Only male mice were studied — sex differences in melanocortin signaling and alcohol consumption are well-documented. The nonselective MCR agonist MTII activates multiple receptor subtypes (MC3R and MC4R), so the specific receptor mediating the anti-drinking effect is unknown. Intracerebral drug delivery is not clinically practical; systemic peptide delivery or small-molecule MCR agonists would be needed for human treatment. The DID model, while validated, captures only one pattern of problematic drinking. Long-term effects and potential for tolerance were not assessed.

How to read the evidence

This is a preclinical mouse study combining observational (IHC peptide expression) and interventional (site-directed drug delivery) approaches. The bidirectional manipulation (agonist reduces, antagonist increases drinking) provides strong mechanistic evidence, though translation to human alcohol use disorder is not established.

When this study was published

Published in 2016, this study is about a decade old but remains relevant as melanocortin-targeted therapies continue to be developed and the overlap between feeding and addiction neurocircuitry is increasingly recognized.

The bigger picture

The melanocortin system has been best known for its role in appetite regulation — MC4R mutations cause severe obesity. This study extends melanocortin's role to alcohol consumption, adding to growing evidence that the brain circuits controlling food intake and substance use are deeply intertwined. The concept that binge drinking disrupts the same peptide systems as binge eating suggests that drugs targeting the melanocortin pathway could potentially treat both conditions. Melanotan-II, while primarily known as a research compound (and controversially used for tanning and sexual function), demonstrates pharmacological proof of concept here for addiction applications.

Questions still open

Could systemically administered melanocortin receptor agonists reduce binge drinking in humans without requiring direct brain injection?
Is the anti-drinking effect mediated specifically through MC4R, MC3R, or both — and would a selective agonist be safer?
Do the melanocortin peptide changes observed with binge drinking also occur in human alcohol use disorder?

Common questions

What are melanocortin peptides and what do they normally do?

Melanocortins are a family of peptide hormones that regulate appetite, energy balance, skin pigmentation, and inflammation. The two key players here are α-MSH (which suppresses appetite and reward-seeking) and AgRP (which stimulates appetite). This study found that binge drinking tips the balance: it reduces α-MSH and increases AgRP in brain reward centers, essentially creating a state that promotes more drinking — a cycle that a melanocortin receptor agonist could potentially break.

Could a melanocortin drug be used to treat alcoholism in people?

It's a promising direction but still early. The study showed that activating melanocortin receptors in a specific brain region reduced binge drinking in mice — but the drug was injected directly into the brain, which isn't practical for patients. The next step would be developing melanocortin drugs that can be taken by mouth or injection and reach the relevant brain regions. Some melanocortin receptor agonists are already approved for other conditions (like setmelanotide for genetic obesity), which could potentially be repurposed.

Read the original research

Lateral hypothalamic melanocortin receptor signaling modulates binge-like ethanol drinking in C57BL/6J mice.

Addiction biology, 21(4), 835-46

View on PubMed ↗Publisher’s paper ↗

Citation

Sprow, Gretchen M; Rinker, Jennifer A; Lowery-Gointa, Emily G; Sparrow, Angela M; Navarro, Montserrat; Thiele, Todd E. (2016). Lateral hypothalamic melanocortin receptor signaling modulates binge-like ethanol drinking in C57BL/6J mice.. Addiction biology, 21(4), 835-46. https://doi.org/10.1111/adb.12264